Literature DB >> 7682226

Expression of the human hematopoietic progenitor cell antigen CD34 in vascular and spindle cell tumors.

P R Cohen1, R P Rapini, A I Farhood.   

Abstract

The human hematopoietic progenitor cell antigen is known as CD34. This antigen is present on normal bone marrow progenitor cells and vascular endothelial cells. We used the monoclonal antibody anti-CD34 and immunoperoxidase staining techniques to evaluate the expression of CD34 in benign and malignant vascular and spindle cell tumors. All of the 42 vascular lesions, except two of three lesions of intravascular papillary endothelial hyperplasia, demonstrated diffuse membraneous staining of moderate to strong intensity of their endothelial cells. Also, normal placentas (five) showed similar staining. All neurofibromas (12), three of five neuromas, and one of four neurilemmomas revealed moderate to strong, diffuse, membraneous staining. Five of eight piloleiomyomas, two of seven angioleiomyomas, and one of five uterine leiomyomas showed focal to diffuse, and weak to moderate, membraneous staining in the smooth muscle component. Six dermatofibrosarcoma protuberans were studied: generalized, strongly positive membraneous staining was present in four. All specimens showed staining of the normal endothelial cells and the cells surrounding the hair follicles (bulge area), sebaceous glands, and eccrine glands. No staining was demonstrated in any of the following fibrohistiocytic tumors: atypical fibroxanthomas (two), fibrous dermatofibromas (23), giant cell tumor of tendon sheath (one), and hemosiderotic dermatofibromas (18). Melanocytic tumors [Spitz nevi (three) and spindle cell superficial spreading malignant melanoma (one)], Merkel cell carcinomas (six), and spindle cell squamous cell carcinomas (two) did not stain with anti-CD34. Glomus tumors (two) and a hemangiopericytoma were also negative except for their vascular channels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682226     DOI: 10.1111/j.1600-0560.1993.tb01243.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  7 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

2.  Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas.

Authors:  E Poblet; F Gonzalez-Palacios; F J Jimenez
Journal:  Virchows Arch       Date:  1996-07       Impact factor: 4.064

3.  Measurement of vascularity as a diagnostic and prognostic tool for well differentiated thyroid tumours: comparison of different methods of assessing vascularity.

Authors:  N A Wong; J Willott; M J Kendall; E A Sheffield
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

4.  Immunoblot analysis of CD34 expression in histologically diverse neoplasms.

Authors:  Y Natkunam; R V Rouse; S Zhu; C Fisher; M van De Rijn
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 5.  How does the Schwann cell lineage form tumors in NF1?

Authors:  Steven L Carroll; Nancy Ratner
Journal:  Glia       Date:  2008-11-01       Impact factor: 8.073

6.  ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study.

Authors:  Corinne Bouvier; François Bertucci; Philippe Métellus; Pascal Finetti; André Maues de Paula; Fabien Forest; Karima Mokhtari; Catherine Miquel; Daniel Birnbaum; Alexandre Vasiljevic; Anne Jouvet; Jean-Michel Coindre; Anderson Loundou; Dominique Figarella-Branger
Journal:  Acta Neuropathol Commun       Date:  2013-05-09       Impact factor: 7.801

Review 7.  Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.

Authors:  Jody F Longo; Shannon M Weber; Brittany P Turner-Ivey; Steven L Carroll
Journal:  Adv Anat Pathol       Date:  2018-09       Impact factor: 4.571

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.